Neuronetics stock: Q3 revenue rises as loss narrows

Published on 11/12/2026 at 13:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock traded at 1.46 euros on Thursday afternoon in Berlin. Third-quarter revenue rose as Greenbrook clinics delivered stronger growth.

Key points for investors

Third-quarter revenue increased 12.5% year over year, led by stronger Greenbrook revenue.
Adjusted EBITDA turned positive while the net loss narrowed sharply from the prior-year quarter.
Neuronetics kept its 2026 revenue outlook unchanged and raised the lower end of its gross-margin outlook.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics reported stronger revenue and improved profitability for the third quarter ended September 30, 2026. In its November 4 release, the company said total revenue increased 12.5% year over year to 42.0 million US dollars, while Greenbrook revenue rose 20.1% to 26.2 million US dollars. The results were published by Neuronetics.

Revenue growth led by Greenbrook

NeuroStar revenue increased 1.8% to 15.8 million US dollars. The company said the overall increase was primarily driven by continued growth in the Greenbrook clinic business.

Gross margin expanded to 52.2% from 45.9% a year earlier. Operating expenses fell 13% to 21.3 million US dollars, helping income from operations turn positive at 0.5 million US dollars, compared with an operating loss of 7.3 million US dollars in the prior-year quarter.

Loss narrows as outlook holds

Adjusted EBITDA turned positive at 1.9 million US dollars, compared with a loss of 4.7 million US dollars in the third quarter of 2025. Net loss attributable to Neuronetics stockholders narrowed to 1.7 million US dollars, or 0.02 US dollars per share, from 9.0 million US dollars, or 0.13 US dollars per share.

Management kept its full-year 2026 revenue outlook at 160 million to 164 million US dollars. The gross-margin outlook is now 49% to 50%, compared with 48% to 50% previously, while operating-expense guidance was reduced to 92.5 million to 95.5 million US dollars.

Current trading reference

Neuronetics stock traded at 1.46 euros on Lang & Schwarz at 13:27 CET on Thursday, November 12, 2026. The company trades under the ticker STIM on Nasdaq, and the quote provides a current euro-based trading reference for investors.